Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MYO 
Myomo Inc (MYO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: MYO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.1
1 Year Target Price $5.1
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.18% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.83M USD | Price to earnings Ratio - | 1Y Target Price 5.1 |
Price to earnings Ratio - | 1Y Target Price 5.1 | ||
Volume (30-day avg) 5 | Beta 1.47 | 52 Weeks Range 0.80 - 7.17 | Updated Date 10/12/2025 |
52 Weeks Range 0.80 - 7.17 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.87% | Operating Margin (TTM) -47.56% |
Management Effectiveness
Return on Assets (TTM) -21.22% | Return on Equity (TTM) -68.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 31600760 | Price to Sales(TTM) 1 |
Enterprise Value 31600760 | Price to Sales(TTM) 1 | ||
Enterprise Value to Revenue 0.78 | Enterprise Value to EBITDA -0.82 | Shares Outstanding 37801070 | Shares Floating 29298475 |
Shares Outstanding 37801070 | Shares Floating 29298475 | ||
Percent Insiders 6.99 | Percent Institutions 66.14 |
Upturn AI SWOT
Myomo Inc
Company Overview
History and Background
Myomo, Inc. was founded in 2004 and is a commercial-stage medical robotics company offering innovative solutions for individuals with neurological disorders such as stroke, spinal cord injury, and brachial plexus injury. It is focused on helping people regain movement in their paralyzed or weakened arms and hands.
Core Business Areas
- MyoPro Orthosis: Designs, develops, and commercializes the MyoPro, a powered upper extremity orthosis, used to restore function to the paralyzed or weakened arms and hands of individuals suffering from neurological disorders such as stroke, spinal cord injury, and brachial plexus injury.
Leadership and Structure
Paul R. Gudonis is the Chairman and Chief Executive Officer. The company has a board of directors and an executive management team responsible for strategic direction and operations.
Top Products and Market Share
Key Offerings
- MyoPro Orthosis: The MyoPro is a custom-fitted, powered brace that uses sensors to detect a useru2019s faint muscle signals and then powers their arm and hand to perform activities of daily living. Market share data is difficult to pinpoint precisely but they are a major player within the small powered orthotics market. Competitors include Ottobock and ReWalk Robotics who offer exoskeletons targeting similar neurological conditions, but often for leg function.
Market Dynamics
Industry Overview
The industry consists of companies that develop and manufacture medical devices for rehabilitation and assistance of individuals with neurological and musculoskeletal disorders. It is a growing market due to the aging population and increasing prevalence of stroke and other neurological conditions.
Positioning
Myomo occupies a niche market within the broader rehabilitation robotics industry, focusing specifically on upper extremity orthoses. Their competitive advantage lies in their unique MyoPro technology that translates faint muscle signals into functional movement.
Total Addressable Market (TAM)
The TAM for upper extremity rehabilitation devices is estimated to be in the hundreds of millions of dollars. Myomo is positioned to capture a significant share of this market with its innovative MyoPro technology.
Upturn SWOT Analysis
Strengths
- Proprietary MyoPro technology
- First mover advantage in upper extremity orthoses
- FDA-cleared product
- Established reimbursement pathways
Weaknesses
- Limited financial resources
- High cost of product
- Reliance on insurance reimbursement
- Small sales team
Opportunities
- Expanding market for rehabilitation robotics
- Increasing awareness of MyoPro benefits
- Partnerships with rehabilitation centers and hospitals
- Developing new applications for MyoPro technology
Threats
- Competition from larger medical device companies
- Changes in reimbursement policies
- Technological advancements by competitors
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Ottobock (Private)
- ReWalk Robotics (RWLK)
- Ekso Bionics (EKSO)
Competitive Landscape
Myomo differentiates itself through its unique MyoPro technology. However, it faces competition from larger, more established companies with greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Myomo has experienced revenue growth in recent years, driven by increased sales of the MyoPro. However, the company is not yet profitable.
Future Projections: Analyst projections for Myomo's future growth are based on factors such as increasing market adoption of the MyoPro and expansion into new markets.
Recent Initiatives: Recent initiatives include expanding the sales team, developing new MyoPro applications, and pursuing partnerships with rehabilitation centers.
Summary
Myomo has innovative technology with good market potential, but it is a smaller company with limited financial resources. It needs to continue to grow revenue and manage its expenses to achieve profitability. Competition and reimbursement challenges are key areas to watch.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Myomo Inc. Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Myomo Inc
Exchange NYSE MKT | Headquaters Burlington, MA, United States | ||
IPO Launch date 2017-06-12 | President, CEO & Chairman Mr. Paul R. Gudonis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 184 | Website https://myomo.com |
Full time employees 184 | Website https://myomo.com | ||
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.